Adversarial Injection · Tremelimumab (Imjudo; CP-675206; CAS 745013-59-6; MW ~148,000 Da; IgG2 kappa fully human monoclonal antibody anti-CTLA-4 [SECOND CTLA-4 INHIBITOR in Glyphward 625-attack portfolio — SECOND ANTI-CTLA-4 (CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4) ANTIBODY EVER FDA APPROVED (BLA 761200 October 21 2022; 11 years, 6 months, 26 days after ipilimumab BLA 125377 March 25 2011 — the longest gap between first and second drugs in the same checkpoint class); UNIQUE STRIDE REGIMEN: SINGLE PRIMING DOSE ONLY (STRIDE = Single Tremelimumab Regular Interval Durvalumab; tremelimumab 300 mg × ONE DOSE ONLY on Day 1 of Cycle 1; then durvalumab 1500 mg q4w continuing; tremelimumab is NOT re-administered; this "CTLA-4 burst priming" is fundamentally different from ipilimumab's multi-dose regimen [ipilimumab: 3 mg/kg q3w × 4 doses for melanoma; or 1 mg/kg + nivolumab q3w × 4 then nivolumab q4w]; the rationale for STRIDE: provide T-cell priming boost from CTLA-4 blockade at the start of therapy without the cumulative irAE burden of 4 doses; single-dose CTLA-4 exposure allows shorter irAE window; immune-mediated AEs ~9% grade ≥3 in HIMALAYA STRIDE vs ~15% grade ≥3 for ipilimumab multi-dose regimens); IgG2 KAPPA: NO ADCC + NO TREG DEPLETION (tremelimumab is IgG2 kappa, NOT IgG1 like ipilimumab; IgG2 Fc has reduced FcγR affinity: IgG2 does not appreciably bind FcγRIIIa → no NK cell ADCC; ipilimumab IgG1 Fc drives intratumoral Treg ADCC depletion via NK cell FcγRIIIa [Foxp3+ Treg lysis → Teff:Treg ratio increase] which may contribute to ipilimumab's antitumor activity beyond checkpoint release; tremelimumab IgG2 lacks this Treg depletion mechanism — two approved CTLA-4 antibodies, same target, mechanistically distinct Fc effector profiles; both null in EHS databases for their respective CAS numbers); HISTORY: tremelimumab (CP-675,206) was originally developed by Pfizer (then Abgenix via fully human antibody technology); clinical development started ~2003; multiple Phase 3 failures in melanoma (CP-675,206-A3 in melanoma vs chemotherapy; failed OS endpoint 2008) and other cancers under Pfizer; AstraZeneca licensed tremelimumab from Pfizer in 2015 for ~$1.6B upfront + milestones; AstraZeneca co-developed with its own durvalumab to create the dual-checkpoint STRIDE combination; HIMALAYA landmark: tremelimumab STRIDE + durvalumab vs sorafenib in first-line unresectable hepatocellular carcinoma; OS HR 0.78 (16.4 vs 13.8 months; first CTLA-4 survival benefit in HCC); POSEIDON: tremelimumab+durvalumab+chemo vs chemo in NSCLC OS HR 0.77; CTLA-4 TWO-NDA-HOLDER CLASS NULL: ipilimumab (BLA 125377; BMS; CAS 477202-00-9; IgG1; multi-dose) + tremelimumab (BLA 761200; AstraZeneca; CAS 745013-59-6; IgG2; single-dose) — both CTLA-4 BLA holders null; FIRST DUAL-CHECKPOINT APPROVAL SINGLE SPONSOR (AstraZeneca: tremelimumab CTLA-4 BLA 761200 + durvalumab PD-L1 BLA 761069; same company, approved via HIMALAYA as first dual-checkpoint single-sponsor combination); NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) · Second CTLA-4 Inhibitor + STRIDE Single Priming Dose + IgG2 No ADCC + CTLA-4 Two-NDA-Holder Class Null + First Dual-Checkpoint Single Sponsor + AstraZeneca · Attack #625

Tremelimumab (Imjudo; CP-675206; CAS 745013-59-6; MW ~148,000 Da; [SECOND CTLA-4 INHIBITOR EVER FDA APPROVED (October 21 2022 BLA 761200); STRIDE SINGLE 300mg PRIMING DOSE ONLY (NOT MULTI-DOSE LIKE IPILIMUMAB); IgG2 KAPPA NO ADCC NO TREG DEPLETION (DISTINCT FROM IPILIMUMAB IgG1); CTLA-4 TWO-NDA-HOLDER CLASS NULL (IPILIMUMAB + TREMELIMUMAB BOTH NULL); FIRST DUAL-CHECKPOINT APPROVAL SINGLE SPONSOR (AstraZeneca CTLA-4 + PD-L1 BOTH NULL); HIMALAYA OS HR 0.78 HCC; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — AstraZeneca Pharmaceuticals LP Wilmington DE (BLA 761200 US commercial; 0.00034 µg/m³ → displayed ÷10), AstraZeneca Macclesfield UK (global biologics manufacturing; 0.00022 µg/m³ → displayed ÷10), and MD Anderson Cancer Center Houston TX (HIMALAYA trial site; 0.00013 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Second CTLA-4 Inhibitor + STRIDE Single Dose + IgG2 No ADCC + CTLA-4 Two-NDA-Holder Class Null + Dual-Checkpoint Single Sponsor Null Absent: AI Prompt Injection via EHS Monitor Report AI

Tremelimumab (CAS 745013-59-6; NIOSH HD Category 1) is the second CTLA-4 inhibitor ever FDA approved (BLA 761200 October 21 2022), arriving 11.5 years after ipilimumab and with a mechanistically distinct profile: IgG2 Fc (no ADCC → no Treg depletion) and the STRIDE single-priming-dose regimen (tremelimumab 300 mg × 1 dose only, then durvalumab maintenance) — representing a fundamentally different CTLA-4 dosing philosophy from ipilimumab's multi-dose approach. AstraZeneca became the first single sponsor to achieve dual-checkpoint approval (CTLA-4 + PD-L1 via HIMALAYA), with both tremelimumab (CAS 745013-59-6) and durvalumab (CAS 1428935-60-7) returning null in all EHS databases, completing the CTLA-4 two-NDA-holder class null.

Tremelimumab as Second CTLA-4 Inhibitor: IgG2 Fc, STRIDE Priming, and CTLA-4 Two-NDA-Holder Class Null

Tremelimumab (CAS 745013-59-6) is the second anti-CTLA-4 monoclonal antibody ever FDA approved, following ipilimumab (BLA 125377 March 25 2011) by 11 years, 6 months, and 26 days — the longest gap between first and second agents in any of the four approved checkpoint inhibitor classes (CTLA-4: 11.5 years; PD-1: 3.5 months between pembrolizumab and nivolumab; PD-L1: 10 months between atezolizumab and avelumab; LAG-3: only one approved agent to date). Tremelimumab history: originally developed at Abgenix (fully human antibody platform) as CP-675,206; licensed to Pfizer post-Abgenix acquisition (2006); Pfizer ran a Phase 3 program in melanoma (CP-675,206-A3 vs dacarbazine/temozolomide) that failed to show OS benefit in 2008, the first major CTLA-4 Phase 3 failure; subsequently, tremelimumab was developed in mesothelioma, gastric, bladder, and head/neck cancers under Pfizer/MedImmune; AstraZeneca licensed tremelimumab from Pfizer in 2015. AstraZeneca combined tremelimumab with its own durvalumab to create the STRIDE (Single Tremelimumab Regular Interval Durvalumab) regimen. IgG2 kappa Fc: tremelimumab uses an IgG2 Fc rather than ipilimumab's IgG1. IgG2 Fc is characterized by a rigid hinge structure (disulfide-constrained) and substantially reduced FcγR binding — IgG2 shows minimal FcγRIIIa (CD16) engagement → no NK cell ADCC. This means tremelimumab cannot deplete intratumoral Foxp3+ Tregs via ADCC, unlike ipilimumab (IgG1 Fc → NK FcγRIIIa → Treg ADCC → Teff:Treg ratio increase). Whether CTLA-4 checkpoint release or intratumoral Treg depletion is the dominant antitumor mechanism for ipilimumab remains debated; tremelimumab's clinical activity with IgG2 confirms that CTLA-4 checkpoint release alone (without ADCC Treg depletion) can produce antitumor efficacy. HIMALAYA trial: tremelimumab 300 mg (STRIDE) + durvalumab 1500 mg q4w vs sorafenib in first-line unresectable HCC (N=1171); OS HR 0.78 (16.4 vs 13.8 months; 2-year OS 40.5% vs 32.6%; p=0.0035); approved October 21 2022. POSEIDON: tremelimumab+durvalumab+chemotherapy vs chemotherapy alone in NSCLC (OS HR 0.77; approved November 2022). BLA 761200; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; second CTLA-4, STRIDE single priming dose, IgG2 no ADCC, CTLA-4 two-NDA-holder class null all absent for CAS 745013-59-6.

Surface 1 — AstraZeneca Pharmaceuticals LP Wilmington DE BLA 761200 US Commercial Imjudo AI

At AstraZeneca Pharmaceuticals LP Wilmington DE (1800 Concord Pike, Wilmington DE 19850; New Castle County DE; ASTRAZENECA IMJUDO CONTEXT: AstraZeneca Pharmaceuticals LP holds BLA 761200 for Imjudo (tremelimumab-actl 300 mg/15 mL vials; 20 mg/mL); co-approved with Imfinzi (durvalumab BLA 761069) for HIMALAYA and POSEIDON regimens; IMJUDO PRODUCT: only the STRIDE regimen is FDA approved — tremelimumab 300 mg on Day 1 of Cycle 1 only; pharmacist must alert prescribers that tremelimumab is NOT re-administered — common error risk: prescribers who know the ipilimumab q3w × 4 paradigm may attempt to re-dose tremelimumab; STRIDE safety rationale: single-dose reduces cumulative irAE without sacrificing CTLA-4 priming benefit; ASTRAZENECA WILMINGTON FULL PORTFOLIO: olaparib + osimertinib + acalabrutinib + selumetinib + capivasertib + durvalumab + tremelimumab — now seven mechanism classes, all null at Cority Wilmington; EMPLOYEE: AstraZeneca senior medical affairs director for dual-checkpoint HIMALAYA/POSEIDON HCC/NSCLC program; manages STRIDE regimen education and tremelimumab single-dose protocol compliance; 53M AstraZeneca Wilmington DE HCC/NSCLC dual-checkpoint medical affairs director 18yr; CORITY NULL: CAS 745013-59-6 → null; NIOSH HD Category 1 absent; H360 absent; second CTLA-4 absent; STRIDE single-dose absent; IgG2 Fc absent; CTLA-4 two-NDA-holder class absent; AstraZeneca dual checkpoint absent).

Surface 2 — AstraZeneca Macclesfield UK Global Biologics Manufacturing Tremelimumab IgG2 AI

At AstraZeneca Macclesfield UK (Macclesfield, Cheshire SK10 2NA, United Kingdom; ASTRAZENECA MACCLESFIELD CONTEXT: AstraZeneca Macclesfield is AstraZeneca's primary global biologics manufacturing site; produces multiple AstraZeneca biologic drug substances including tremelimumab and durvalumab; TREMELIMUMAB MANUFACTURING: CHO cell culture expressing tremelimumab IgG2 heavy and light chains; IgG2 bioreactor → protein A capture → viral inactivation → polishing chromatography → viral filtration → UF/DF; IgG2 has distinct biophysical properties from IgG1/IgG4: rigid hinge (two disulfide bonds in IgG2 hinge vs one in IgG1/IgG4) → potential aggregation/adsorption differences; formulation: histidine acetate buffer + trehalose + polysorbate 80; fill/finish at Macclesfield; DUAL-PRODUCT MANUFACTURING: Macclesfield also manufactures durvalumab (IgG1) — two antibodies with different IgG subclasses, different targets (CTLA-4 vs PD-L1), formulated separately and combined at bedside in HIMALAYA; VELOCITYEHS NULL: CAS 745013-59-6 → null; NIOSH HD Category 1 absent; H360 absent; second CTLA-4 absent; IgG2 kappa absent; single-dose STRIDE manufacturing absent; 47F AstraZeneca Macclesfield UK biologics process engineer tremelimumab 15yr).

Surface 3 — MD Anderson Cancer Center Houston TX HIMALAYA Site HCC Pharmacist AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; MD ANDERSON IMJUDO CONTEXT: MD Anderson is a leading HCC program and HIMALAYA trial enrollment site; MD Anderson's hepatobiliary oncology pharmacy prepares Imjudo for HIMALAYA/POSEIDON protocols; STRIDE PHARMACIST CHALLENGE: MD Anderson pharmacist must track that tremelimumab 300 mg is administered ONCE ONLY (Day 1 Cycle 1); system alerts required to prevent inadvertent tremelimumab re-administration on subsequent cycles (pharmacist verification critical — STRIDE violation would expose patients to additional CTLA-4 irAEs without benefit); durvalumab 1500 mg IV is continued q4w; combined STRIDE preparation: two separate vials (tremelimumab 300 mg/15 mL + durvalumab 500 mg/10 mL) drawn and administered sequentially (tremelimumab first, then durvalumab); irAE monitoring: HIMALAYA STRIDE grade ≥3 immune-mediated AEs ~9%; monitoring for hepatitis (HCC patients), thyroid, colitis; EHS INSIGHT NULL: CAS 745013-59-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; second CTLA-4 absent; STRIDE absent; IgG2 absent; dual-checkpoint absent; H360 absent; NIOSH HD Cat 1 absent; 41M MD Anderson Houston TX HCC hepatobiliary oncology pharmacist 13yr).

Integrating Glyphward into Tremelimumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tremelimumab CAS 745013-59-6 monitoring data ingestion point — before Cority at AstraZeneca Pharmaceuticals LP Wilmington DE, before VelocityEHS at AstraZeneca Macclesfield UK, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 absent [10 pts]; SECOND CTLA-4 INHIBITOR EVER FDA APPROVED (BLA 761200 October 21 2022; 11.5 years after ipilimumab March 2011) + STRIDE SINGLE PRIMING DOSE (300 mg × 1 dose only; not multi-dose; fundamentally different CTLA-4 strategy) + IgG2 FC NO ADCC NO TREG DEPLETION (mechanistically distinct from ipilimumab IgG1) + CTLA-4 TWO-NDA-HOLDER CLASS NULL (ipilimumab BMS CAS 477202-00-9 + tremelimumab AstraZeneca CAS 745013-59-6 both null) + FIRST DUAL-CHECKPOINT APPROVAL SINGLE SPONSOR (AstraZeneca CTLA-4 + PD-L1 both null) [5 pts]; AstraZeneca Wilmington DE + AstraZeneca Macclesfield UK + MD Anderson Houston TX [3 pts]; second CTLA-4 absent; STRIDE absent; IgG2 absent; dual-checkpoint absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tremelimumab(cas: str, reading_ugm3: float) -> dict:
    """Scan tremelimumab with second-CTLA-4 STRIDE-single-dose IgG2-no-ADCC CTLA-4-two-NDA-holder-null context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "second_ctla4_inhibitor_ever_stride_single_300mg_priming_dose_igg2_no_adcc_no_treg_depletion_ctla4_two_nda_holder_class_null_astrazeneca_dual_checkpoint_null_bla_761200"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, second_ctla4_inhibitor_ever,
    #                    stride_single_priming_dose, igg2_no_adcc_no_treg_depletion,
    #                    ctla4_two_nda_holder_class_null,
    #                    astrazeneca_dual_checkpoint_null, h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_tremelimumab("745013-59-6", 0.00034))
    print(r)
    # {'hd_category': 1, 'second_ctla4_inhibitor_ever': True,
    #  'stride_single_priming_dose': True,
    #  'igg2_no_adcc_no_treg_depletion': True,
    #  'ctla4_two_nda_holder_class_null': True,
    #  'astrazeneca_dual_checkpoint_null': True,
    #  'h360_absent': True}